Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Arora, Brijesh; Kumar, Lalit; Kumari, Mamta; Sharma, Atul; WADHAWA, JYOTI; Kochupillai, V.

doi:10.1055/s-0041-1733114

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But, the frequencies of thrombocytopenia and hypopigmentation were varying when compared with other Indian studies. [7][8][9] However, the changes in the frequency of ADRs may be due to the different size of populations in various studies mentioned (n = 36-450), which cannot be ruled out.…”

Section: Discussionmentioning

confidence: 99%

“…O'Brien et al [2] (n=51) (%) Kantarjian et al [6] (n=450) (%) Arora et al [7] (n=73) (%) Deshmukh et al [8] (n=97) (%)…”

Section: Common Adrs Present Study (N=119) (%)mentioning

confidence: 99%

“…[2,6] Previous reports from India show varied frequencies of adverse events compared with the Western studies. [7][8][9] Considering these aspects, the present study was the surveillance of the ADRs associated with the use of imatinib in CML patients. Further, the ADR information collected was assessed using the World Health Organization scale for their causality and the Hartwig scale for the severity of their reactions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

Francis¹,

Palaniappan²,

Dubashi³

et al. 2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

Objective:To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital.Materials and Methods:The study was carried out by the Departments of Pharmacology and Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India. The study was carried out from March 2012 to February 2014. The ADRs were reported in a suspected Adverse Drug Reaction Reporting form, provided by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare, Government of India. The ADRs were analyzed for their pattern, causality and severity.Results:A total of 326 ADRs from 81 patients were reported during the study period. The hematological toxicities were much more prominent than the non-hematological toxicities in this study. The prevalence of thrombocytopenia (21.17%) was higher compared with other reactions. Further analysis showed that most of the ADRs were mild to moderate in nature. The causality assessment revealed that the majority of the ADRs belonged to the possible category.Conclusion:The present study in a tertiary care hospital suggests that hematological toxicities are predominant in CML patients treated with imatinib mesylate. The blood and lymphatic system (38.96%) was the most affected, with imatinib therapy and thrombocytopenia (21.17%) being the most commonly encountered ADRs in the present study. Thorough monitoring of ADRs is warranted for better treatment outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…O'Brien et al [2] (n=51) (%) Kantarjian et al [6] (n=450) (%) Arora et al [7] (n=73) (%) Deshmukh et al [8] (n=97) (%)…”

Section: Common Adrs Present Study (N=119) (%)mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

Francis¹,

Palaniappan²,

Dubashi³

et al. 2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

show abstract

The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

Tobaiqy,

Helmi,

MacLure

et al. 2023

Int J Clin Pharm

View full text Add to dashboard Cite

Total Leukocyte Counts and the Requirement of Dose Reduction due to Cytopenias as Prognostic Indicators Affecting Response to Imatinib in Chronic Myeloid Leukemia

Tripathi

Kumar

Ramaswamy

2011

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Imatinib is a tyrosine kinase inhibitor and is considered the first line of non stem cell transplantation treatment for patients diagnosed with CML. We evaluated the response rates and adverse reactions to Imatinib in our patients and tried to identify factors which affected the response to Imatinib. Eighty-four patients were diagnosed on the basis of clinical and haematological variables with confirmation by FISH, detecting Philadelphia chromosome or bcr-abl translocation and were then started on oral capsule Imatinib. A complete haematological response was seen in 78.04% patients, while complete cytogenetic response (CCR) was seen in 12.2% of patients and major cytogenetic response (MCR) was seen in 64.63% of patients. It was found that that a greater total leukocyte count (TLC) on presentation had a negative correlation with cytogenetic response. Cytopenias were seen in 36 patients (43.82%). 34.9% of patients having CCR/MCR required dose reduction while 73.6% of patients not achieving CCR/MCR required dose reduction. This was a significant difference, confirmed on statistical analysis (P < 0.05; P = 0.019), establishing the negative prognostic value of dose reduction due to cytopenias.

show abstract

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

Cited by 4 publications

References 26 publications

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study

The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

Total Leukocyte Counts and the Requirement of Dose Reduction due to Cytopenias as Prognostic Indicators Affecting Response to Imatinib in Chronic Myeloid Leukemia

Contact Info

Product

Resources

About